Autolus Therapeutics (FRA:6A3A) FFO


FRA:6A3A Autolus Therapeutics PLC FRA:6A3A
67 GF Score
Price €1.37
GF Value €16.89
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Autolus Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

FRA:6A3A
67GF Score
Autolus Therapeutics PLC FRA:6A3A
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Autolus Therapeutics (FRA:6A3A) Overvalued in 2026?

Based on GuruFocus' analysis, Autolus Therapeutics stock appears to be undervalued. The current stock price of €1.37 is trading 91.9% below its estimated GF Value™ of €16.89. GuruFocus considers Autolus Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:6A3A:

  • FFO:
  • GF Value™: €16.89 vs. price of €1.37 (91.9% below fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the FRA:6A3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Autolus Therapeutics Business Description

Other Exchanges AUTL:USA6A3A:Germany
Address 191 Wood Lane, The MediaWorks, London, GBR, W12 7FP
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
67GF Score

Get the complete analysis for FRA:6A3A

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.37
Price
€16.89
GF Value